WEEKLY EPIDEMIOLOGY BULLETIN

NATIONAL EPIDEMIOLOGY UNIT, MINISTRY OF HEALTH & WELLNESS, JAMAICA

Weekly Spotlight

Breast Cancer Treatment



People with an abnormal breast lump should seek medical care, even if the lump does not hurt. Most breast lumps are not cancer. Breast lumps that are cancerous are more likely to be successfully treated when they are small and have not spread to nearby lymph nodes.

Breast cancers may spread to other areas of the body and trigger other

symptoms. Often, the most common first detectable site of spread is to the lymph nodes under the arm although it is possible to have cancerbearing lymph nodes that cannot be felt. Over time, cancerous cells may spread to other organs including the lungs, liver, brain and bones. Once they reach these sites, new cancer-related symptoms such as bone pain or headaches may appear.

Treatment

Treatment for breast cancer depends on the subtype of cancer and how much it has spread outside of the breast to lymph nodes (stages II or III) or to other parts of the body (stage IV).

Doctors combine treatments to minimize the chances of the cancer coming back (recurrence). These include:

surgery to remove the breast tumour radiation therapy to reduce recurrence risk in the breast and surrounding tissues medications to kill cancer cells and prevent spread, including hormonal therapies, chemotherapy or targeted biological therapies.

Treatments for breast cancer are more effective and are better tolerated when started early and taken to completion.

Surgery may remove just the cancerous tissue (called a lumpectomy) or the whole breast (mastectomy). Surgery may also remove lymph nodes to assess the cancer's ability to spread.

Radiation therapy treats residual microscopic cancers left behind in the breast tissue and/or lymph nodes and minimizes the chances of cancer recurring on the chest wall.

Advanced cancers can erode through the skin to cause open sores (ulceration) but are not necessarily painful. Women with breast wounds that do not heal should seek medical care to have a biopsy performed.

https://www.who.int/news-room/fact-sheets/detail/breast-cancer

EPI WEEK 39




- Syndromic Surveillance
- Accidents
- Violence

Pages 2-4



Class 1 Notifiable Events

Page 5



COVID-19

Page 6



Influenza

Page 7



Dengue Fever

Page 8



Research Paper

Page 9

SENTINEL SYNDROMIC SURVEILLANCE

Sentinel Surveillance in Jamaica



A syndromic surveillance system is good for early detection of and response to public health events.

Sentinel surveillance occurs when selected health facilities (sentinel sites) form a network that reports on certain health conditions on a regular basis, for example, weekly. Reporting is mandatory whether or not there are cases to report.

Jamaica's sentinel surveillance system concentrates on visits to sentinel sites for health events and syndromes of national importance which are reported weekly (see pages 2 -4). There are seventy-eight (78) reporting sentinel sites (hospitals and health centres) across Jamaica.

Table showcasing the Timeliness of Weekly Sentinel Surveillance Parish Reports for the Four Most Recent Epidemiological Weeks – 36 to 39 of 2023

Parish health departments submit reports weekly by 3 p.m. on Tuesdays. Reports submitted after 3 p.m. are considered late.

KEY:

Yellow- late submission on Tuesday

Red – late submission after Tuesday


Epi week	Kingston and Saint Andrew	Saint Thomas	Saint Catherine	Portland	Saint Mary	Saint Ann	Trelawny	Saint James	Hanover	Westmoreland	Saint Elizabeth	Manchester	Clarendon
	Δ					20)23						
36	On	On	On	On	On	On	On	On	On	On	On	On	Late
	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	(T)
37	On	On	On	On	On	On	On	Late	On	On	On	On	On
	Time	Time	Time	Time	Time	Time	Time	(T)	Time	Time	Time	Time	Time
38	On	On	Late	Late	On	On	On	On	On	On	On	On	On
	Time	Time	(W)	(T)	Time	Time	Time	Time	Time	Time	Time	Time	Time
39	On	On	Late	On	On	On	On	On	On	On	On	On	On
	Time	Time	(W)	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time

REPORTS FOR SYNDROMIC SURVEILLANCE

UNDIFFERENTIATED FEVER

Temperature of $>38^{\circ}C$ /100.4°F (or recent history of fever) with or without an obvious diagnosis or focus of infection.









INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued



FEVER AND NEUROLOGICAL

Temperature of >38°C /100.4°F (or recent history of fever) in a previously healthy person with or without headache and vomiting. The person must also have meningeal irritation, convulsions, altered consciousness, altered sensory manifestations or paralysis (except AFP).



FEVER AND HAEMORRHAGIC

Temperature of $>38^{\circ}C$ /100.4°F (or recent history of fever) in a previously healthy person presenting with at least one haemorrhagic (bleeding) manifestation with or without jaundice.




FEVER AND JAUNDICE


Temperature of $>38^{\circ}C/100.4^{\circ}F$ (or recent history of fever) in a previously healthy person presenting with jaundice.

The epidemic threshold is used to confirm the emergence of an epidemic in order to implement control measures. It is calculated using the mean reported cases per week plus 2 standard deviations.


Weekly Visits to Sentinel Sites for Fever and Neurological Symptoms 2022 and 2023 vs. Weekly Threshold: Jamaica



Weekly visits to Sentinel Sites for Fever and Haemorrhagic 2022 and 2023 vs Weekly Threshold; Jamaica



Fever and Jaundice cases: Jamaica, Weekly Threshold vs Cases 2022 and 2023





NOTIFICATIONS-All clinical sites



INVESTIGATION
REPORTS- Detailed Follow
up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued




October 13, 2023 ISSN 0799-3927

ACCIDENTS

Any injury for which the cause is unintentional, e.g. motor vehicle, falls, burns, etc.



Weekly visits to Sentinel Sites for Accidents by Age Group 2023 vs Weekly Threshold; Jamaica



≥5 y/o Cases

<5 y/o Cases</p>

— Epidemic Threshold≥5


Epidemic Threshold<5

VIOLENCE

Any injury for which the cause is intentional, e.g. gunshot wounds, stab wounds, etc.



Weekly visits to Sentinel Sites for Violence by Age Group 2023 vs Weekly Threshold; Jamaica



≥5 y.o

<5 y.o

<5 Epidemic Threshold


-≥5 Epidemic Threshold

GASTROENTERITIS

Inflammation of the stomach and intestines, typically resulting from bacterial toxins or viral infection and causing vomiting and diarrhoea.



Weekly visits to Sentinel Sites for Gastroenteritis All ages 2023 vs Weekly Threshold; Jamaica



NOTIFICATIONS-All clinical



INVESTIGATION **REPORTS-** Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued





October 13 , 2023 ISSN 0799-3927

CLASS ONE NOTIFIABLE EVENTS

Comments

				1 TITE (I			
				ed YTD ^a	AFP Field Guides from		
CLASS 1 EVENTS		CURRENT YEAR 2023	PREVIOUS YEAR 2022	WHO indicate that for an effective surveillance			
					system, detection rates for		
	Accidental Po	oisoning	257β	167^{β}	AFP should be 1/100,000		
7	Cholera		0	0	population under 15 years old (6 to 7) cases annually.		
ON	Dengue Hem	orrhagic Fever ^γ	See Dengue page below	See Dengue page below	old (0 to 1) cases annually.		
ATI	COVID-19 (S	SARS-CoV-2)	3690	54880	Pertussis-like syndrome		
GRN	Hansen's Dis	ease (Leprosy)	0	0	and Tetanus are clinically		
L /INTERN INTEREST	Hepatitis B		47	26	confirmed classifications.		
NATIONAL /INTERNATIONAL INTEREST	Hepatitis C		24	2	——————————— γ Dengue Hemorrhagic		
√NC	HIV/AIDS		N/A	N/A	Fever data include Dengue		
A TI(Malaria (Imp	oorted)	3	2	related deaths;		
Ž	Meningitis		24	18	δ Figures include all deaths		
	Monkeypox		3	14	associated with pregnancy		
EXOTIC/			0	0	reported for the period.		
UNUSUAL	Plague				ε CHIKV IgM positive		
H IGH MORBIDITY, MORTALITY		eal Meningitis	0	0	cases		
H IGH RBIDI RTAL)	Neonatal Teta	anus	0	0	^θ Zika PCR positive cases		
H ORI	Typhoid Feve	er	0	0	β Updates made to prior		
$\Sigma \Sigma$	Meningitis H	/Flu	0	0	weeks.		
	AFP/Polio		0	0	^α Figures are cumulative		
	Congenital R	ubella Syndrome	0	0	totals for all		
7.0	Congenital Sy	yphilis	0	0	epidemiological weeks year to date.		
MES	Fever and	Measles	0	0	to dute.		
SPECIAL PROGRAMM	Rash	Rubella	0	0			
l 90	Maternal Dea	${\rm nths}^{\delta}$	39	57			
, PR	Ophthalmia N	Veonatorum	105	68			
IAI	Pertussis-like		0	0			
SPEC	Rheumatic Fe		0	0			
	Tetanus		0	2			
	Tuberculosis		34	33			
	Yellow Fever		0	0			
Chikungunya ^c			0	0			
	Zika Virus ^θ		0	0	NA- Not Available		





INVESTIGATION REPORTS- Detailed Follow up for all Class One Events




HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued




COVID-19 Surveillance Update

March 10, 2020 - EW 39, 2023





^{*} PCR or Antigen tests are used to confirm cases



COVID-19 Outcomes


Outcomes	EW 39	Total	
ACTIVE *2 weeks*		96	
DIED – COVID	0	3690	
Related Died - NON	0	341	
COVID Died - Under	U	541	
Investigation	0	267	
Recovered and discharged	3	103207	
Repatriated	0	93	
Total		156599	

^{*}Vaccination programme March 2021 – YTD


3128 COVID-19 Related Deaths since March 1, 2021 – YTD Vaccination Status among COVID-19 Deaths

■ Workplace Cluster

■ Local Transmission (Not Epi Linked) ■ Under Investigation



COVID-19 Parish Distribution and Global Statistics



COVID-19 WHO Global Statisticts EW36-EW39					
Epi Week	Confirmed Cases	Deaths			
36	128,207	497			
37	136,776	521			
38	88,864	355			
39	124,444	968			
Total (4weeks)	478,291	2,341			

COVID19 Cases by Parish Total Cases Confirmed COVID19 _____ 8938 - 17992 4646 17992 5221 Cases by Parish 17993 - 28183 11552 4028 - 5990 28184 - 41762 8825 4972 4028 8937 7875 5990 Legend EW 39 Cases med COVID19 Cases by = 4 - 6 Parish October 1 to 7, 2023 7-9 10-16

6 NOTIFICATIONS-All clinical sites



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued





^{*} Total as at current Epi week


NATIONAL SURVEILLANCE UNIT **INFLUENZA REPORT**

EW 39

September 24 – September 30, 2023 Epidemiological Week 39

	EW 39	YTD
SARI cases	2	450
Total Influenza positive Samples	0	181
Influenza A	0	17
H3N2	0	1
H1N1pdm09	0	15
Not subtyped	0	1
Influenza B	0	164
B lineage not determined	0	2
B Victoria	0	162
Parainfluenza	0	1
Adenovirus	0	2
RSV	0	14


Weekly visits to Sentinel Sites for Influenza-like Illness (ILI) All ages 2023 vs Weekly Threshold; Jamaica



Epi Week Summary

During EW 39, two(2) SARI admissions were reported.


Jamaica: Percentage of Hospital Admissions for Severe Acute Respiratory Illness (SARI 2023) (compared with 2011-2021)



Caribbean Update EW 39

Caribbean: Influenza activity continues to exhibit a declining trend over the past 4 EWs. During this period, the predominant influenza viruses have been B/Victoria, with lesser circulation of influenza A, primarily A(H1N1)pdm09. RSV activity has remained low. SARS-CoV-2 activity shows an increasing trend with intermediate to high levels of circulation. ILI and SARI cases have demonstrated a declining trend over the past 4 EWs.

Distribution of Influenza and Other Respiratory Viruses Under Surveillance by EW, Jamaica - 2023



All clinical



INVESTIGATION **REPORTS-** Detailed Follow up for all Class One Events








Dengue Bulletin

September 24- September 30, 2023 Epidemiological Week 39

Epidemiological Week 39





Reported suspected and confirmed dengue with symptom onset in week 39 of 2023


	2023*			
	EW 39	YTD		
Total Suspected & Confirmed Dengue Cases	271	1649		
Lab Confirmed Dengue cases	50	370		
CONFIRMED Dengue Related Deaths	0	0		

Symptoms of Dengue fever Febrile phase Critical phase sudden-onset fever hypotension pleural effusion mouth and nose ascites bleeding gastrointestinal bleeding muscle and joint pains Recovery phase altered level of vomiting consciousness rash itching diarrhea slow heart rate

Points to note:

- *Figure as at September 30, 2023
- Only PCR positive dengue cases are reported as confirmed.
- IgM positive cases are classified as presumed dengue.

Suspected dengue cases for 2020, 2021, 2022 and 2023 versus monthly mean, alert, and epidemic thresholds (2007-2022)







INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued





October 13 , 2023 ISSN 0799-3927

RESEARCH PAPER

Abstract

NHRC_22_O4

The Prevalence of Anaemia in Jamaicans 15 Years and Older

Grant A¹, Younger-Coleman N², McFarlaneS², Francis D³, Tulloch-Reid M², Davidson T¹, Ferguson T², Webster-Kerr K¹, Wilks R²

¹Ministry of Health, Kingston, Jamaica, ²Caribbean Institute for Health Research, Mona, Kingston 7, ³School of Health and Human Performance, Georgia College and State University, Milledgeville, GA, USA

Background: Iron deficiency is a common cause of anaemia and is associated with increased maternal and perinatal morbidity, cognitive impairment and decreased economic productivity However, there are limited data on anaemia in the Jamaican population

Objective: To estimate the prevalence of anemia in Jamaicans aged ≥ 15 years.

Methods: The Jamaica Health and Lifestyle Survey (JHLS III) was a cross-sectional nationally representative survey conducted in 2016/17 involving 2,807 participants. WHO criteria were used to define anaemia (<13g/dl-males;< 12g/dl-females) and classify severity as mild (11-12.9 g/dl-males;11-11.9 g/dl-females), moderate (8-10.9 g/dl-both sexes) and severe (< 8 g/dl-both sexes). Iron deficiency was defined as serum ferritin <15 μg/ml. Statistical analysis yielded weighted prevalence estimates, accounting for survey design.

Results: Anaemia prevalence % (95% CI) was: 17.6% (14.0, 21.7) overall, 9.5% (6.5, 13.8) in males, and 25.0% (20.4, 30.2).in females. For males, anaemia prevalence was highest in elderly men, while for women it was highest in women of reproductive age. Anaemia severity in the population was: 11.5% (8.5, 15.3) mild, 5.3% (4.0, 6.9) moderate and 0.8% (0.4, 1.7) severe. Iron deficiency was present in 9.9% (8.4, 11.7), and was higher in women 17.8% (14.8, 21.3) vs. men 1.9% (8.4, 11.7), (p< 0.01).

Conclusion: Anaemia affects approximately one fifth of the population and may be higher among women of reproductive age and older individuals. The negative impact on birth and other outcomes makes this a public health concern. Data from the JHLS III provides baseline information for tracking global targets to be attained by 2025.



The Ministry of Health and Wellness 24-26 Grenada Crescent Kingston 5, Jamaica Tele: (876) 633-7924

Email: surveillance@moh.gov.jm



NOTIFICATIONS-All clinical sites



INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued

